T1742

T1742 is an autophagy inhibitor targeting ATG5. T1742 blocks and disrupts protein-protein interactions between ATG5 and ATG16L1, and between ATG5 and TECAIR.T 1742 inhibits autophagy in living cells via reduced autophagosome formation and downregulated ATG8 -PE conjugation. T1742 can be used to study autophagy mechanisms ^{[1] [2] [3]}.

In Vitro, T1742 (2.5-40 μM; 16 h) dose-dependently inhibits autophagy in COS-7 cells^[1]. T1742 (1.25-40 μM; 6 h) dose-dependently reduces LC3-II levels, indicating autophagy inhibition, in COS-7, U-937, and THP-1 cells^[1]. T1742 blocks the ATG5-ATG16L1 and ATG5-TECAIR protein-protein interactions in vitro with IC₅₀ values of 1.1 μM and 1.7 μM, respectively^[2].

References:
[1]. Xiang H, et al. Discovery of Small-Molecule Autophagy Inhibitors by Disrupting the Protein-Protein Interactions Involving Autophagy-Related 5. J Med Chem. 2023 Feb 23;66(4):2457-2476.
[2]. Xiang H, et al. Discovery of small-molecule inhibitors for the protein-protein interactions involving ATG5. Autophagy Rep. 2023;2(1):2215617. Published 2023 May 27.
[3]. Yan D, et al. Molecular dynamics-driven drug discovery. Phys Chem Chem Phys. 2025;27(24):12633-12651. Published 2025 Jun 18.